Corcept Therapeutics (CORT) Net Income towards Common Stockholders (2010 - 2026)

Corcept Therapeutics (CORT) has 17 years of Net Income towards Common Stockholders data on file, last reported at -$31.2 million in Q1 2026.

• For the quarter ending Q1 2026, Net Income towards Common Stockholders fell 253.8% year-over-year to -$31.2 million; the trailing twelve-month figure through Mar 2026 stood at $46.7 million (down 64.77% YoY), and the FY2025 full-year result was $98.2 million, down 29.74% from the prior year.
• Net Income towards Common Stockholders declined to -$31.2 million in Q1 2026, from $23.9 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $46.7 million in Q3 2024 to a low of -$31.2 million in Q1 2026.
• A 5-year average of $24.3 million and a median of $27.4 million in 2022 frame the typical range for Net Income towards Common Stockholders.
• Across the five-year window, Net Income towards Common Stockholders jumped 88.37% in 2023 and slumped 253.8% in 2026, its largest moves.
• Tracing CORT's Net Income towards Common Stockholders over 5 years: stood at $16.5 million in 2022, then jumped by 88.37% to $31.1 million in 2023, then dropped by 2.42% to $30.4 million in 2024, then retreated by 21.34% to $23.9 million in 2025, then sank by 230.53% to -$31.2 million in 2026.
• Business Quant data shows CORT's Net Income towards Common Stockholders at -$31.2 million in Q1 2026, $23.9 million in Q4 2025, and $19.4 million in Q3 2025.